Home » Stocks » KNTE

Kinnate Biopharma, Inc. (KNTE)

Stock Price: $27.64 USD -2.01 (-6.76%)
Updated Apr 19, 2021 2:55 PM EDT - Market open
Market Cap 187.02M
Revenue (ttm) n/a
Net Income (ttm) -35.76M
Shares Out 6.77M
EPS (ttm) -5.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $27.64
Previous Close $29.64
Change ($) -2.01
Change (%) -6.76%
Day's Open 29.31
Day's Range 27.17 - 29.34
Day's Volume 46,577
52-Week Range 24.14 - 48.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers

2 weeks ago - GlobeNewsWire

SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...

4 weeks ago - GlobeNewsWire

SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

2 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other stocks mentioned: AYTU, MYOV, OSMT
3 months ago - Benzinga

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in ...

3 months ago - Benzinga

SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

4 months ago - GlobeNewsWire

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...

Other stocks mentioned: FTCVU, LOKBU, POWW, SBTX, SEER, SGAMU, YQ
4 months ago - Seeking Alpha

KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.

4 months ago - InvestorPlace

Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on Nasdaq und...

4 months ago - Market Watch

Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.

4 months ago - Investors Business Daily

Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 mill...

4 months ago - Market Watch

SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

4 months ago - GlobeNewsWire

Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of that range.

4 months ago - Market Watch

The firm is developing treatments for various cancers using a kinase inhibitory approach.

4 months ago - TheStreet

Kinnate Biopharma, an oncology biotech developing small molecule kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

5 months ago - NASDAQ

Kinnate Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About KNTE

Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we collectively refer to as our Kinnate Discovery Engine, to develop our targeted therapies. We focus our discovery and d... [Read more...]

Industry
Biotechnology
IPO Date
Dec 3, 2020
CEO
Nima Farzan
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
KNTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 80.93% from the latest price.

Price Target
$50.00
(80.93% upside)
Analyst Consensus: Buy